Passkey Therapeutics

Passkey Therapeutics is pioneering a new class of medicines called Synergistic Multifunctional Therapeutics (SMThs), designed to address complex diseases by engaging multiple biological targets simultaneously. The companys proprietary Locksmith platform maps synergistic pharmacology using human genetics, biology, and pharmacology data across 4,000 approved drugs and 600 billion genetic variants to identify powerful drug combinations. Because Locksmith identifies combinations using approved and late-stage drugs, programs can bypass traditional preclinical development and proceed directly to human proof-of-concept clinical trials. Passkey partners with pharma companies to unlock clinic-ready combination therapies across oncology and other complex diseases with unmet need.